We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Issues Guidance on Postapproval Manufacturing Changes for Synthetics
FDA Issues Guidance on Postapproval Manufacturing Changes for Synthetics
The FDA issued guidance on how sponsors of synthetic drugs should approach post-approval manufacturing process changes — listing examples of low, medium and high risk changes.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor